RE:RE:RE:RE:Incoming
Maersk wrote: Bedenke, was Du Dir wnschst, es knnte Dir gewhrt werden.
According to StatsCan, prior to legalization in Canada on 10/2018 there were 345k medical marijuana clients who purchased marijuana from licensed producers. In March 2023 there were 212k medical marijuana clients, a decrease of 38%. There was a corresponding decrease in sales of medical marijuana, which declined by 34% between Q4/2018 and Q4/2022.
Definitely a decline due to Rec. However, ACB is taking full advantage in Canada, along with TLRY in International medicinal sales. Which will only increase dramatically with n 2024.
Updated stats from ACB ER
Net revenue rose to $63.4 million, up solidly compared to $48 million in the year-ago period. Overall, medical cannabis generated $43.8 million in net revenue, up 42% from last year.
By segment, international medical revenue was $18.4 million, up 126% from last year, and Canadian medical cannabis was $25.4 million, up 11% year over year. The performance of our high-margin medical channels was largely due to the positive market reaction to the launch of our new Canadian-grown high-potency cultivars in our key European markets and to the continued growth of the Australian medical market.